LENSAR jumps as cataract surgery system wins FDA approval

LENSAR

13/06/2022 12:56

** Shares of LENSAR Inc  LNSR.O  jump 24.3% to a
two-and-a-half-month high of $8.03 premarket
    ** Stock set for best day since December 2020, if gains
hold, and is among the top gainers across U.S. exchanges 
    ** The maker of medical tech for eye conditions says the FDA
has approved its marketing application for ALLY, its tech system
for cataract surgery  urn:newsml:reuters.com:*:nBw6lwRCLa
    ** Co plans a controlled, targeted initial launch in Q3,
followed by complete roll-out in 2023
    ** Stock has gained 7.8% this year through last close   

 (Reporting by Ruhi Soni in Bengaluru;)
 ((Ruhi.Soni@thomsonreuters.com
Twitter: https://twitter.com/ruhithere))